학술논문

Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis.
Document Type
article
Source
JHEP reports : innovation in hepatology. 2(1)
Subject
ALP
alkaline phosphatase
ALT
alanine aminotransferase
Aging
BMI
body mass index
DNAm
DNA methylation
ELF
enhanced liver fibrosis
FDR
false discovery rate
GGT
gamma-glutamyltransferase
IBD
inflammatory bowel disease
IL
interleukin
LOXL2
lysyl oxidase-like-2
NASH
non-alcoholic steatohepatitis
PSC
primary sclerosing cholangitis
SMA
smooth muscle actin
UDCA
ursodeoxycholic acid
biomarker
inflammatory bowel disease
primary sclerosing cholangitis
prognosis
ursodeoxycholic acid
ALP
alkaline phosphatase
ALT
alanine aminotransferase
BMI
body mass index
DNAm
DNA methylation
ELF
enhanced liver fibrosis
FDR
false discovery rate
GGT
gamma-glutamyltransferase
IBD
IL
interleukin
LOXL2
lysyl oxidase-like-2
NASH
non-alcoholic steatohepatitis
PSC
SMA
smooth muscle actin
UDCA
Language
Abstract
Background & Aims:A DNA methylation (DNAm) signature derived from 353 CpG sites (the Horvath clock) has been proposed as an epigenetic measure of chronological and biological age. This epigenetic signature is accelerated in diverse tissue types in various disorders, including non-alcoholic steatohepatitis, and is associated with mortality. Here, we assayed whole blood DNAm to explore age acceleration in patients with primary sclerosing cholangitis (PSC). Methods:Using the MethylationEPIC BeadChip (850K) array, DNAm signatures in whole blood were analyzed in 36 patients with PSC enrolled in a 96-week trial of simtuzumab (Ishak F0-1, n = 13; F5-6, n = 23). Age acceleration was calculated as the difference between DNAm age and chronological age. Comparisons between patients with high and low age acceleration (≥ vs. < the median) were made and Cox regression evaluated the association between age acceleration and PSC-related clinical events (e.g. decompensation, cholangitis, transplantation). Results:Age acceleration was significantly higher in patients with PSC compared to a healthy reference cohort (median, 11.1 years, p